-
Lisocabtagene maraleucel, sold
under the
brand name
Breyanzi, is a cell-based gene
therapy used to
treat B-cell lymphomas,
including follicular lymphoma...
- 2023-11-21.
European Medicines Agency (2023-11-10). "
Breyanzi". EMA. "CAR T Cell
Therapy Breyanzi®
Approved as
Relapsed or
Refractory Large B-cell Lymphoma...
-
Brevicon Brevital Sodium Brevoxyl Brexidol 20
brexucabtagene autoleucel (INN)
Breyanzi Briakinumab (USAN, INN)
Brian Care
Bricanyl brifentanil (INN) brimonidine...
- vicleucel)". U.S. Food and Drug
Administration (FDA). 21
April 2021. "
Breyanzi (lisocabtagene maraleucel)". U.S. Food and Drug
Administration (FDA). 4...
- therapies. On
February 5, 2021, the U.S. Food and Drug
Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene
therapy to
treat adult patients...
- acetonide)
Oncology Abecma (idecabtagene vicleucel)
BiCNU (carmustine)
Breyanzi (lisocabtagene maraleucel)
CeeNU (lomustine) Droxia/Hydrea (hydroxycarbamide)...
-
Hemoglobin subunit beta
Sickle cell
disease Lisocabtagene maraleucel (
Breyanzi)
Bristol Myers Squibb autologous CAR-T CD19
Diffuse large B-cell lymphoma...
-
lymphoblastic leukemia: Yescarta,
Tecartus (brexucabtagene autoleucel),
Breyanzi (lisocabtagene maraleucel),
Carvykti (ciltacabtagene autoleucel), Abecma...
-
outside the
House chamber. The U.S. Food and Drug
Administration approves Breyanzi to
treat large B-cell lymphoma.
February 7 The
Tampa Bay
Buccaneers win...
- autoleucel)". FDA. Research,
Center for
Biologics Evaluation and (2022-07-01). "
BREYANZI (lisocabtagene maraleucel)". FDA. Research,
Center for
Biologics Evaluation...
